Enamine and Ewha launch AI drug discovery partnership

Enamine Ltd. and Ewha Womans University’s Global AI Drug Discovery Center signed a memorandum of understanding in Seoul to link AI design with rapid synthesis and testing. The collaboration aims to speed the path from computational ideas to validated drug leads through a closed design-make-test-analyze cycle.

Why it matters: - The partnership is built to close the gap between AI-generated molecules and compounds that can actually be synthesized and tested. - Faster feedback from chemistry and biology can shorten the timeline from virtual idea to validated hit and lead compound. - The deal also connects drug discovery teams in Ukraine and Korea and creates a broader platform for joint research and future commercialization.

What happened: - Enamine Ltd. and the Global AI Drug Discovery Center at Ewha Womans University signed a memorandum of understanding on Oct. 7, 2026. - The signing took place at a ceremony on the Ewha campus in Seoul. - The agreement creates a long-term strategic partnership in AI-driven drug discovery. - The collaboration combines Ewha’s expertise in artificial intelligence, computational chemistry and data-driven drug design with Enamine’s synthetically accessible chemical space, rapid synthesis and biological testing.

The details: - Enamine will give the Center access to in-stock building blocks, screening compounds and its ultra-large REAL chemical spaces for AI-based virtual screening, generative design and model training. - The partners will use a closed design-make-test-analyze cycle. - AI models will search chemical space that Enamine can synthesize. - Experimental results will feed back into the next round of model improvement. - Molecules designed or selected by the Center can be synthesized rapidly from available reagents using reactions with experimentally validated reactivity. - Enamine’s biology team will profile selected compounds on-site with biochemical, biophysical and cell-based assays. - Early ADME studies are included in the testing workflow. - The agreement also covers joint research in synthesizability-aware generative design, ultra-large virtual screening, reaction and property prediction, and generation of high-quality experimental data for model training. - The partners plan to publish results together. - The agreement supports integrated drug discovery offerings for pharmaceutical, biotechnology and academic partners in Korea and worldwide. - The partners will also pursue joint applications to Korean government R&D programs, Horizon Europe and bilateral Korea–Ukraine initiatives. - The deal includes faculty, researcher and student exchanges, plus internships and training in AI-driven drug design and synthetic and medicinal chemistry. - Joint symposiums, workshops and seminars are part of the plan.

Between the lines: - The partnership reflects a broader shift in drug discovery toward systems that reward not just good predictions, but fast synthesis and rapid biological validation. - Enamine’s pitch is that chemical space has value only when compounds can be made efficiently and reproducibly. - Ewha gains access to a large, experimentally grounded discovery engine for training models and testing hypotheses. - The collaboration could help both sides build a shared pipeline for academic work, industry projects and government-funded research.

What's next: - The partners will begin joint research and data-sharing activities under the MOU. - They are expected to advance applications for public funding in Korea, Europe and Korea–Ukraine programs. - Enamine and Ewha also intend to develop project-based discovery offerings for external partners. - Further publications, symposiums and training programs are expected as the collaboration expands.

The bottom line: - Enamine and Ewha are trying to make AI drug discovery more practical by tightly linking computational design to synthesis and testing.